Mechanistic approaching study in COVID-19 patients treated with high doses of vitamin D
Aim: To evaluate angiotensin II (Ang II) and Ang-(1-7) levels and the cytokine profile in patients hospitalized with mild coronavirus disease 2019 (COVID-19) and contrast them with patients with identical clinical conditions but treated with high doses of vitamin D (vitD). Methods: From the 218 pat...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Open Exploration Publishing Inc.
2023-04-01
|
| Series: | Exploration of Medicine |
| Subjects: | |
| Online Access: | https://www.explorationpub.com/Journals/em/Article/1001137 |
| _version_ | 1797833540693393408 |
|---|---|
| author | Mauro G. Silva Felipe Inserra Javier Mariani Laura Antonietti Myriam Nuñez Carlos Tajer León Ferder Pablo I. F. Inserra Fernando Ross Milagro Sánchez Cunto Magalí Bertelli Gabriela de Larrañaga Eliana M. Cela Daniel H. González Maglio Mariela M. Gironacci Walter Manucha |
| author_facet | Mauro G. Silva Felipe Inserra Javier Mariani Laura Antonietti Myriam Nuñez Carlos Tajer León Ferder Pablo I. F. Inserra Fernando Ross Milagro Sánchez Cunto Magalí Bertelli Gabriela de Larrañaga Eliana M. Cela Daniel H. González Maglio Mariela M. Gironacci Walter Manucha |
| author_sort | Mauro G. Silva |
| collection | DOAJ |
| description | Aim: To evaluate angiotensin II (Ang II) and Ang-(1-7) levels and the cytokine profile in patients hospitalized with mild coronavirus disease 2019 (COVID-19) and contrast them with patients with identical clinical conditions but treated with high doses of vitamin D (vitD).
Methods: From the 218 patients recruited (ClinicalTrials.gov NCT04411446), 16 participated in this sub-study and were randomized to a single oral dose of 500,000 IU vitD (n = 10) or placebo (n = 6). Plasmatic Ang II and Ang-(1-7) levels were determined by radioimmunoassay and interleukins (ILs) 1, 6, 8, and 10 and tumor necrosis factor alpha (TNF-α) by enzyme-linked immunosorbent assay before and after treatment. Parallel, serum 25-hydroxyvitamin D3 (25-OH vitD) concentrations as vitD status was measured by a chemiluminescence immunoassay.
Results: A trend towards an increase in Ang-(1-7) and a decrease in Ang II levels were observed in placebo- and vitD-treated COVID-19 patients compared to baseline values. There was no difference in Ang II and Ang-(1-7) levels between placebo- and vitD-treated COVID-19 patients. Similar results were obtained with ILs profile. COVID-19 patients showed an increase in the protective component of the RAS which was not improved by vitD treatment.
Conclusions: VitD did not improve RAS disbalance in COVID-19. Notwithstanding, the authors visualize that acute treatment with high doses of vitD may show a trend to a decline in inflammatory ILs and an increase in protective markers. Finally, the authors would like to highlight the limitations of this preliminary study, namely the small number of patients and the use of a large single bolus dose of vitD rather than lower daily doses for extended periods with prolonged follow-up times. All these factors need special consideration in the designs of new vitD supplementation trials. All these factors need special consideration in the designs of new vitD supplementation trials (ClinicalTrials.gov identifier: NCT04411446). |
| first_indexed | 2024-04-09T14:25:02Z |
| format | Article |
| id | doaj.art-617c065bc300439f8c0f5ce12587b150 |
| institution | Directory Open Access Journal |
| issn | 2692-3106 |
| language | English |
| last_indexed | 2024-04-09T14:25:02Z |
| publishDate | 2023-04-01 |
| publisher | Open Exploration Publishing Inc. |
| record_format | Article |
| series | Exploration of Medicine |
| spelling | doaj.art-617c065bc300439f8c0f5ce12587b1502023-05-04T07:14:49ZengOpen Exploration Publishing Inc.Exploration of Medicine2692-31062023-04-014224625310.37349/emed.2023.00137Mechanistic approaching study in COVID-19 patients treated with high doses of vitamin DMauro G. Silva0Felipe Inserra1Javier Mariani2Laura Antonietti3Myriam Nuñez4Carlos Tajer5León Ferder6Pablo I. F. Inserra7Fernando Ross8Milagro Sánchez Cunto9Magalí Bertelli10Gabriela de Larrañaga11Eliana M. Cela12Daniel H. González Maglio13Mariela M. Gironacci14Walter Manucha15Instituto de Química y Fisicoquímica Biológicas (IQUIFIB), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires 1113, ArgentinaDepartment of Biosciences, Universidad Maimónides, Ciudad Autónoma de Buenos Aires, Buenos Aires 1405, ArgentinaHospital de Alta Complejidad en Red El Cruce-Néstor Kirchner, Florencio Varela, Buenos Aires 1888, ArgentinaHospital de Alta Complejidad en Red El Cruce-Néstor Kirchner, Florencio Varela, Buenos Aires 1888, ArgentinaCátedra de Matemáticas, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires 1113, ArgentinaHospital de Alta Complejidad en Red El Cruce-Néstor Kirchner, Florencio Varela, Buenos Aires 1888, ArgentinaDepartment of Biosciences, Universidad Maimónides, Ciudad Autónoma de Buenos Aires, Buenos Aires 1405, ArgentinaCentro de Estudios Biomédicos, Básicos, Aplicados y Desarrollo (CEBBAD), Universidad Maimónides, CONICET, Buenos Aires 1405, ArgentinaMedical Clinic Section, Clínica Santa Isabel, Ciudad Autónoma de Buenos Aires, Buenos Aires 1406GZJ, ArgentinaMedical Clinic Section, Hospital de Infecciosas Francisco Javier Muñiz, Ciudad Autónoma de Buenos Aires, Buenos Aires 1282AEN, ArgentinaMedical Clinic Section, Hospital de Infecciosas Francisco Javier Muñiz, Ciudad Autónoma de Buenos Aires, Buenos Aires 1282AEN, ArgentinaMedical Clinic Section, Hospital de Infecciosas Francisco Javier Muñiz, Ciudad Autónoma de Buenos Aires, Buenos Aires 1282AEN, ArgentinaCátedra de Inmunología, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires 1113, Argentina; Instituto de Estudios de la Inmunidad Humoral (IDEHU), CONICET-Universidad de Buenos Aires, Buenos Aires 1113, ArgentinaCátedra de Inmunología, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires 1113, Argentina; Instituto de Estudios de la Inmunidad Humoral (IDEHU), CONICET-Universidad de Buenos Aires, Buenos Aires 1113, ArgentinaInstituto de Química y Fisicoquímica Biológicas (IQUIFIB), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires 1113, ArgentinaInstituto de Medicina y Biología Experimental de Cuyo (IMBECU), CONICET-Universidad Nacional de Cuyo, Mendoza 5500, Argentina; Facultad de Ciencias Médicas, Universidad Nacional de Cuyo, Mendoza 5500, ArgentinaAim: To evaluate angiotensin II (Ang II) and Ang-(1-7) levels and the cytokine profile in patients hospitalized with mild coronavirus disease 2019 (COVID-19) and contrast them with patients with identical clinical conditions but treated with high doses of vitamin D (vitD). Methods: From the 218 patients recruited (ClinicalTrials.gov NCT04411446), 16 participated in this sub-study and were randomized to a single oral dose of 500,000 IU vitD (n = 10) or placebo (n = 6). Plasmatic Ang II and Ang-(1-7) levels were determined by radioimmunoassay and interleukins (ILs) 1, 6, 8, and 10 and tumor necrosis factor alpha (TNF-α) by enzyme-linked immunosorbent assay before and after treatment. Parallel, serum 25-hydroxyvitamin D3 (25-OH vitD) concentrations as vitD status was measured by a chemiluminescence immunoassay. Results: A trend towards an increase in Ang-(1-7) and a decrease in Ang II levels were observed in placebo- and vitD-treated COVID-19 patients compared to baseline values. There was no difference in Ang II and Ang-(1-7) levels between placebo- and vitD-treated COVID-19 patients. Similar results were obtained with ILs profile. COVID-19 patients showed an increase in the protective component of the RAS which was not improved by vitD treatment. Conclusions: VitD did not improve RAS disbalance in COVID-19. Notwithstanding, the authors visualize that acute treatment with high doses of vitD may show a trend to a decline in inflammatory ILs and an increase in protective markers. Finally, the authors would like to highlight the limitations of this preliminary study, namely the small number of patients and the use of a large single bolus dose of vitD rather than lower daily doses for extended periods with prolonged follow-up times. All these factors need special consideration in the designs of new vitD supplementation trials. All these factors need special consideration in the designs of new vitD supplementation trials (ClinicalTrials.gov identifier: NCT04411446). https://www.explorationpub.com/Journals/em/Article/1001137covid-19sars-cov-2vitamin d3angiotensin iiangiotensin-(1-7)interleukins |
| spellingShingle | Mauro G. Silva Felipe Inserra Javier Mariani Laura Antonietti Myriam Nuñez Carlos Tajer León Ferder Pablo I. F. Inserra Fernando Ross Milagro Sánchez Cunto Magalí Bertelli Gabriela de Larrañaga Eliana M. Cela Daniel H. González Maglio Mariela M. Gironacci Walter Manucha Mechanistic approaching study in COVID-19 patients treated with high doses of vitamin D Exploration of Medicine covid-19 sars-cov-2 vitamin d3 angiotensin ii angiotensin-(1-7) interleukins |
| title | Mechanistic approaching study in COVID-19 patients treated with high doses of vitamin D |
| title_full | Mechanistic approaching study in COVID-19 patients treated with high doses of vitamin D |
| title_fullStr | Mechanistic approaching study in COVID-19 patients treated with high doses of vitamin D |
| title_full_unstemmed | Mechanistic approaching study in COVID-19 patients treated with high doses of vitamin D |
| title_short | Mechanistic approaching study in COVID-19 patients treated with high doses of vitamin D |
| title_sort | mechanistic approaching study in covid 19 patients treated with high doses of vitamin d |
| topic | covid-19 sars-cov-2 vitamin d3 angiotensin ii angiotensin-(1-7) interleukins |
| url | https://www.explorationpub.com/Journals/em/Article/1001137 |
| work_keys_str_mv | AT maurogsilva mechanisticapproachingstudyincovid19patientstreatedwithhighdosesofvitamind AT felipeinserra mechanisticapproachingstudyincovid19patientstreatedwithhighdosesofvitamind AT javiermariani mechanisticapproachingstudyincovid19patientstreatedwithhighdosesofvitamind AT lauraantonietti mechanisticapproachingstudyincovid19patientstreatedwithhighdosesofvitamind AT myriamnunez mechanisticapproachingstudyincovid19patientstreatedwithhighdosesofvitamind AT carlostajer mechanisticapproachingstudyincovid19patientstreatedwithhighdosesofvitamind AT leonferder mechanisticapproachingstudyincovid19patientstreatedwithhighdosesofvitamind AT pabloifinserra mechanisticapproachingstudyincovid19patientstreatedwithhighdosesofvitamind AT fernandoross mechanisticapproachingstudyincovid19patientstreatedwithhighdosesofvitamind AT milagrosanchezcunto mechanisticapproachingstudyincovid19patientstreatedwithhighdosesofvitamind AT magalibertelli mechanisticapproachingstudyincovid19patientstreatedwithhighdosesofvitamind AT gabrieladelarranaga mechanisticapproachingstudyincovid19patientstreatedwithhighdosesofvitamind AT elianamcela mechanisticapproachingstudyincovid19patientstreatedwithhighdosesofvitamind AT danielhgonzalezmaglio mechanisticapproachingstudyincovid19patientstreatedwithhighdosesofvitamind AT marielamgironacci mechanisticapproachingstudyincovid19patientstreatedwithhighdosesofvitamind AT waltermanucha mechanisticapproachingstudyincovid19patientstreatedwithhighdosesofvitamind |